Document is current
Any future updates will be listed below
-
Authors
Arvin, Ann M.
Fink, Katja
Schmid, Michael A.
Cathcart, Andrea
Spreafico, Roberto
Havenar-Daughton, Colin http://orcid.org/0000-0002-2880-3927
Lanzavecchia, Antonio
Corti, Davide http://orcid.org/0000-0002-5797-1364
Virgin, Herbert W. http://orcid.org/0000-0001-8580-7628
- License Information
-
More Information
Article History
Received: 15 May 2020
Accepted: 6 July 2020
First Online: 13 July 2020
Competing interests
: The authors of this manuscript are employees of, or have other affiliations with, Vir Biotechnology. Vir had to choose how to proceed with mAbs to treat or prevent COVID-19 disease in the light of the evidence surrounding the possibility of ADE as detailed in this review. This review reflects the result of the team of authors carefully reviewing the literature to assess these choices and is provided as a service to the community. Vir has elected to test human mAbs with Fc activity preserved or enhanced, based on the lack of consistent evidence for ADE of disease noted above and evidence that the protective activities and potency of antibodies often involves antibody effector functions. We could have elected to take forward mAbs engineered to lack effector function, and so our antibody-related clinical programmes for SARS-CoV-2 could have moved forward regardless of the outcome of our review. A.M.A.’s contributions were part of her personal outside consulting arrangement with Vir Biotechnology and were not associated with Stanford University.
Free to read: This content has been made available to all.
